Literature DB >> 10479390

Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease.

C von Landenberg1, K J Lackner, P von Landenberg, B Lang, G Schmitz.   

Abstract

The antigenic specificity of anti-phospholipid antibodies (APA) is a matter of intensive investigation. To further characterize these antibodies, we attempted to isolate human monoclonal APA. B-cells of patients with at least one positive test for antibodies against cardiolipin, phosphatidylserine, beta2-glycoprotein I (beta2-GPI) or the lupus anti-coagulant were immortalized by transformation with Epstein-Barr virus and screened for production of specific IgG. Positive pools were fused with a heteromyeloma cell line and APA-secreting clones were isolated by standard procedures. Two monoclonal APA, HL-5B from a 51-year-old man with primary anti-phospholipid syndrome and recurrent cerebral microinfarctions, and RR-7F from a 48-year-old women with systemic lupus erythematosus but no evidence for thrombotic events were obtained. HL-5B is of the IgG2 subtype with lambda light chains, while RR-7F is IgG2 with kappa light chains. Both monoclonals show reactivity against cardiolipin and phosphatidylserine but lack reactivity against beta2-GPI or lupus anti-coagulant activity. To yield the same OD in the cardiolipin and phosphatidylserine ELISAs RR-7F must be used in an approximately 10-fold higher concentration than HL-5B, indicating a lower affinity towards these antigens. Interestingly, both mAPA can bind to cardiolipin in the absence of beta2-GPI. They do not cross-react with dsDNA but show reactivity against oxidized low-density lipoproteins. Analysis of the heavy chain mRNA of HL-5B and RR-7F showed that both are members of the VH3 family. While HL-5B shows extensive somatic mutations in the CDR1 and 2 regions, indicating that it was derived by a T cell-dependent antigen driven process, RR-7F is apparently germline encoded. The two monoclonal APA can be used as tools in further structural and functional analyses. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479390     DOI: 10.1006/jaut.1999.0316

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  8 in total

Review 1.  The roll of Toll-like receptors in the antiphospholipid syndrome.

Authors:  Julia Hurst; Mareike Lorenz; Nadine Prinz; Philipp von Landenberg
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

2.  Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies.

Authors:  Nadine Müller-Calleja; Svenja Ritter; Anne Hollerbach; Tanja Falter; Karl J Lackner; Wolfram Ruf
Journal:  Blood Adv       Date:  2018-05-08

3.  Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay.

Authors:  Karl Egerer; Dirk Roggenbuck; Thomas Büttner; Barbara Lehmann; Annushka Kohn; Philipp von Landenberg; Rico Hiemann; Eugen Feist; Gerd-Rüdiger Burmester; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2011-07-21       Impact factor: 5.156

4.  Lipid presentation by the protein C receptor links coagulation with autoimmunity.

Authors:  Nadine Müller-Calleja; Anne Hollerbach; Jennifer Royce; Svenja Ritter; Denise Pedrosa; Thati Madhusudhan; Sina Teifel; Myriam Meineck; Friederike Häuser; Antje Canisius; T Son Nguyen; Johannes Braun; Kai Bruns; Anna Etzold; Ulrich Zechner; Susanne Strand; Markus Radsak; Dennis Strand; Jian-Ming Gu; Julia Weinmann-Menke; Charles T Esmon; Luc Teyton; Karl J Lackner; Wolfram Ruf
Journal:  Science       Date:  2021-03-12       Impact factor: 63.714

Review 5.  Toll-like receptors play a crucial part in the pathophysiological activity of antiphospholipid antibodies.

Authors:  Philipp von Landenberg
Journal:  Auto Immun Highlights       Date:  2011-06-07

6.  A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome.

Authors:  Gerd Gladigau; Philipp Haselmayer; Inge Scharrer; Markus Munder; Nadine Prinz; Karl Lackner; Hansjörg Schild; Pamela Stein; Markus P Radsak
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

Review 7.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

8.  Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers.

Authors:  Dirk Roggenbuck; Maria Orietta Borghi; Valentina Somma; Thomas Büttner; Peter Schierack; Katja Hanack; Claudia Grossi; Caterina Bodio; Paolo Macor; Philipp von Landenberg; Francesco Boccellato; Michael Mahler; Pier Luigi Meroni
Journal:  Arthritis Res Ther       Date:  2016-05-21       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.